These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 12208224

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.
    Sabatine MS, Morrow DA, Giugliano RP, Murphy SA, Demopoulos LA, DiBattiste PM, Weintraub WS, McCabe CH, Antman EM, Cannon CP, Braunwald E.
    Circulation; 2004 Feb 24; 109(7):874-80. PubMed ID: 14757697
    [Abstract] [Full Text] [Related]

  • 23. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
    Bosch X, Marrugat J, Sanchis J.
    Cochrane Database Syst Rev; 2013 Nov 08; (11):CD002130. PubMed ID: 24203004
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
    Ferguson JJ, Antman EM, Bates ER, Cohen M, Every NR, Harrington RA, Pepine CJ, Theroux P, NICE-3 Investigators.
    Am Heart J; 2003 Oct 08; 146(4):628-34. PubMed ID: 14564315
    [Abstract] [Full Text] [Related]

  • 26. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
    Gurm HS, Tamhane U, Meier P, Grossman PM, Chetcuti S, Bates ER.
    Circ Cardiovasc Interv; 2009 Jun 08; 2(3):230-6. PubMed ID: 20031720
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Use of glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing coronary revascularization.
    Popma JJ.
    Haemostasis; 1999 Dec 08; 29 Suppl S1():69-71. PubMed ID: 10629407
    [Abstract] [Full Text] [Related]

  • 29. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
    Bosch X, Marrugat J, Sanchis J.
    Cochrane Database Syst Rev; 2013 Oct 18; (10):CD002130. PubMed ID: 24136036
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Characteristics, treatment and outcome of patients with non-ST-elevation acute coronary syndromes and multivessel coronary artery disease: observations from PURSUIT (platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrelin therapy).
    Breeman A, Mercado N, Lenzen M, van den Brand MM, Harrington RA, Califf RM, Topol EJ, Simoons ML, Boersma E, PURSUIT Investigators.
    Cardiology; 2002 Oct 18; 98(4):195-201. PubMed ID: 12566649
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
    Galli M, Maggioni AP, Vassanelli C, Tavazzi L.
    Ital Heart J Suppl; 2000 Feb 18; 1(2):202-11. PubMed ID: 10731377
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [GPIIB/IIIA blockade after high-risk angioplasty: new perspectives].
    Smiri Z, Lahidheb D, Hajlaoui N, Barakett N, Rahal N, Azzouzi F, Fehri W, Mhenni H, Haouala H.
    Tunis Med; 2003 Feb 18; 81 Suppl 8():617-24. PubMed ID: 14608749
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
    Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators.
    N Engl J Med; 1998 May 21; 338(21):1488-97. PubMed ID: 9599103
    [Abstract] [Full Text] [Related]

  • 40. The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis.
    Glaser R, Glick HA, Herrmann HC, Kimmel SE.
    J Am Coll Cardiol; 2006 Feb 07; 47(3):529-37. PubMed ID: 16458131
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.